Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 13;13(2):279. doi: 10.3390/cancers13020279

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The biological function of the signaling lymphocytic activation molecule family receptor (SLAMF) 7 on multiple myeloma (MM) cells and mechanism of action of elotuzumab. (A) On MM cells, SLAMF7 is associated with adhesion to bone marrow stroma cells (BMSCs) and elotuzumab blocks MM cell adhesion to BMSCs. Elotuzumab stimulates robust natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) via the Fc–CD16 interaction (B), directly induces activating signal transduction in NK cells (C), improves NK-cell-mediated cytotoxicity in response to the SLAMF7–SLAMF7 interaction (D), and enhances macrophage (Mφ)-mediated antibody-dependent cellular phagocytosis through the CD16 receptor (E). (F) SLAMF7 promotes MM cell growth via SHP2–ERK signaling in response to binding with soluble SLAMF7 (sSLAMF7), and elotuzumab suppressed MM cell growth promoted by SLAMF7–sSLAMF7 interactions in vitro.